The clinical and cost-effectiveness of different treatment pathways for neuropathic pain (NP)

Fox-Rushby J
Record ID 32007000330
English
Authors' objectives: Neuropathic pain is a form of pain that is caused by damage to nerves. It is extremely unpleasant and often resistant to treatment, so adversely affects the quality of life of millions of people. Over the past 20 years specific painkillers have been developed to treat this type of pain. However, these drugs differ in terms of how well or how long they relieve pain for. Many doctors are not clear which are the most appropriate drugs to use or in what order, especially as many of the new drugs are expensive and may have unwanted side-effects. The purpose of this research is to compare the effectiveness, side effects and costs of different treatment plans for patients with neuropathic pain. This will help to decide which treatment options provide the most benefit given available resources. In pulling together everything that is known about all the different treatment plans available, it is likely that we will find also some gaps in current knowledge. Therefore this research will also be able to highlight what would be most useful to know more about to help future decisions.
Details
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Comparative Study
  • Treatment Outcome
  • Neuralgia
Contact
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
Copyright: <p>2009 Queen's Printer and Controller of HMSO</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.